Navigation Links
Five New Clinical Studies Show Value of Masimo PVI & PI
Date:10/17/2008

to the 'gold standard' measure-through-motion-and-low-perfusion performance of Masimo SET(R) Oxygen Saturation (SpO2), Pulse Rate (PR) and Perfusion Index (PI).

About Masimo

Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in Sect
'/>"/>

SOURCE Masimo
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
2. Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society
3. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
4. Sysmex Announces Clinical Laboratory Software Name Change
5. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Covance Decides to Pursue Its Original Preclinical Strategy in China
8. Satyam Partners with Oracle to Provide Clinical Development Applications
9. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
10. Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins
11. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- BioScrip, Inc. (NASDAQ: BIOS ) today announced ... Global Healthcare Conference to be held June 3-6, 2013 ... Richard Smith , President and Chief Executive ... Financial Officer, will present on Monday, June 3, 2013 ... About BioScrip BioScrip, Inc. provides comprehensive infusion and ...
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan Racing ... cord blood stem cell banking and therapeutics, announced today ... No. 16 Acorn Stairlifts Indy car driven by ... remainder of the IZOD IndyCar 2013 season.   ... work to support awareness of umbilical cord blood banking ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... May 23, 2013 The New Jersey ... industries, Black Data Processing Associates (BDPA), is hosting its ... 8, 2013. This all-day event will encourage students and ... the ins and outs from many of the industries’ ... at the New Jersey Institute of Technology, the event ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2
... ... 2009 and is now serving 7 of the Top 10 pharmaceutical and 3 of the ... ... 2009 -- OpenQ, a leading provider of technology and information solutions for the life sciences ...
... , , WAYNE, Pa., July 17 ... ENCO ), a full service multinational clinical research organization ... clinical trials and patient registries to many of the ... completed the previously announced sale of the Company,s U.S. ...
... , HOPKINTON, Mass., July 16 ... a conference call discussing the company,s second quarter 2009 financial results ... President and Chief Executive Officer and Peter McAree, Chief Financial Officer, ... and the company,s outlook for the future. , ...
Cached Biology Technology:OpenQ Posts a 200% Revenue Growth in the First Half of 2009 2Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 2Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 3Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 4Caliper Life Sciences' Second Quarter 2009 Financial Results Conference Call Notice 2
(Date:5/23/2013)... By discovering the new mechanism by which estrogen suppresses ... revealed a potential new approach toward treating certain liver ... and colleagues believe they are changing long-held views in ... issue of the journal Science Signaling . , ... years has been that only receptors located in the ...
(Date:5/23/2013)... Some prostate cancer patients unnecessarily undergo surgery or ... differences between slow-growing and aggressive forms of the ... Johns Hopkins Medical Institutes are developing technology that ... opt for relatively mild treatments or take drastic ... Anant Madabhushi, an associate professor of biomedical engineering ...
(Date:5/23/2013)... world are billions of animal and plant specimens from ... all stacked, stored and preserved in jars and collection ... critical to understanding how the Earth,s biodiversity is changing ... if only the information were easily accessible. , A ... of a team from the University of Colorado Boulder, ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
... been shed on proteorhodopsin, the light-sensitive protein found in ... of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) and ... when the ability to respire oxygen is impaired, bacterium ... carry out vital life processes. , ...
... onset of type 1 diabetes in mice prone to ... on the surface of immune T-cells. According to the ... January issue of the journal Diabetes, have significant implications ... More than 700,000 Americans have type 1 diabetes, an ...
... soon be able to cultivate new tomato varieties without ... This is the conclusion of the STW-sponsored thesis by ... to earn his doctorate on 3 April 2007. Finkers ... resistant to grey mould. The leading company De Ruiter ...
Cached Biology News:Shedding new light on proteorhodopsin 2Shedding new light on proteorhodopsin 3Antibody therapy prevents type 1 diabetes in mice 2Research on grey mould offers possible breakthrough in tomato cultivation 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Goat polyclonal to Glucose Dehydrogenase ( Abpromise for all tested applications). Antigen: Glucose Dehydrogenase (Bacillus species)...
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Biology Products: